AmpliPhi Investors Want More Detail on C3J Therapeutics Merger

AmpliPhi Biosciences Corp. didn’t give investors enough information to evaluate a planned merger with C3J Therapeutics Inc., an April 25 suit said.

The biotechnology firm’s proxy statement left out details on AmpliPhi’s financial projections, the complaint filed in the U.S. District Court for the Western District of Washington said. Nor did the statement disclose whether confidentiality agreements prevented AmpliPhi from entertaining other offers, the suit said.

Some existing C3J shareholders have committed to investing around $10 million in the post-merger company, according to an AmpliPhi press release.

The company scheduled a special meeting for May 8.

Causes of Action: ...